|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
136,480,000 |
Market
Cap: |
3.66(B) |
Last
Volume: |
503,160 |
Avg
Vol: |
501,799 |
52
Week Range: |
$26.23 - $39.94 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Related Products |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Perrigo is a provider of over-the-counter health and wellness solutions that can be self-managed. Co.'s segments are as follows: Consumer Self-Care Americas, which is focused primarily on the sale of self-care products in categories including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements; Consumer Self-Care International, which develops, manufactures, markets, and distributes European consumer self-care brands in the upper respiratory, pain and sleep-aids, digestive health, vitamins, minerals and supplements; and Prescription Pharmaceuticals, which develops, manufactures, and markets a portfolio of generic prescription drugs.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Papa Joseph C |
President and CEOChairman |
|
2009-11-25 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,500 |
80,631 |
|
- |
|
Papa Joseph C |
President and CEOChairman |
|
2009-11-25 |
4 |
S |
$40.58 |
$811,578 |
D/D |
(20,000) |
82,131 |
|
- |
|
Papa Joseph C |
President and CEOChairman |
|
2009-11-25 |
4 |
OE |
$17.29 |
$345,800 |
D/D |
20,000 |
102,131 |
|
- |
|
Shah Jatin |
Sr VP & Chief Scientific Offic |
|
2009-11-25 |
4 |
S |
$40.22 |
$71,081 |
D/D |
(1,760) |
7,675 |
|
- |
|
Farrington Thomas |
Senior VP and CIO |
|
2009-11-24 |
4 |
S |
$39.89 |
$66,140 |
D/D |
(1,658) |
298 |
|
- |
|
Farrington Thomas |
Senior VP and CIO |
|
2009-11-24 |
4 |
OE |
$20.50 |
$40,098 |
D/D |
1,956 |
1,956 |
|
- |
|
Gibbons David T |
Director |
|
2009-11-24 |
4 |
S |
$39.88 |
$1,196,517 |
D/D |
(30,000) |
75,051 |
|
- |
|
Jandernoa Michael J |
Director |
|
2009-11-23 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,430 |
2,020,486 |
|
- |
|
Jandernoa Michael J |
Director |
|
2009-11-19 |
4 |
GD |
$0.00 |
$0 |
I/I |
738 |
2,021,916 |
|
- |
|
Jandernoa Michael J |
Director |
|
2009-11-18 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,580 |
2,022,654 |
|
- |
|
Shah Jatin |
Sr VP & Chief Scientific Offic |
|
2009-11-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,000 |
9,435 |
|
- |
|
Shah Jatin |
Sr VP & Chief Scientific Offic |
|
2009-11-17 |
4 |
S |
$39.75 |
$473,484 |
D/D |
(11,910) |
12,435 |
|
- |
|
Shah Jatin |
Sr VP & Chief Scientific Offic |
|
2009-11-17 |
4 |
OE |
$14.69 |
$180,035 |
D/D |
10,910 |
24,345 |
|
- |
|
Jandernoa Michael J |
Director |
|
2009-11-16 |
4 |
D |
$39.66 |
$13,393,444 |
I/I |
(337,670) |
2,024,234 |
|
- |
|
Jandernoa Michael J |
Director |
|
2009-11-16 |
4 |
GD |
$0.00 |
$0 |
I/I |
4,346 |
2,361,904 |
|
- |
|
Kingma Todd W |
Executive VP, General Counsel |
|
2009-11-13 |
4 |
S |
$40.00 |
$576,000 |
D/D |
(14,400) |
23,019 |
|
- |
|
Kingma Todd W |
Executive VP, General Counsel |
|
2009-11-13 |
4 |
OE |
$14.69 |
$211,536 |
D/D |
14,400 |
37,419 |
|
- |
|
Lebel Refael |
EVP & GM Perrigo Israel |
|
2009-11-13 |
4 |
S |
$40.12 |
$802,322 |
D/D |
(20,000) |
25,751 |
|
- |
|
Lebel Refael |
EVP & GM Perrigo Israel |
|
2009-11-13 |
4 |
OE |
$14.69 |
$303,160 |
D/D |
20,000 |
45,751 |
|
- |
|
Kochan Sharon |
Executive VP U.S. Generics |
|
2009-11-13 |
4 |
S |
$40.18 |
$117,044 |
D/D |
(2,913) |
15,593 |
|
- |
|
Kochan Sharon |
Executive VP U.S. Generics |
|
2009-11-13 |
4 |
OE |
$20.50 |
$59,717 |
D/D |
2,913 |
18,506 |
|
- |
|
Kingma Todd W |
Executive VP, General Counsel |
|
2009-11-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,700 |
23,019 |
|
- |
|
Kingma Todd W |
Executive VP, General Counsel |
|
2009-11-12 |
4 |
S |
$39.73 |
$117,637 |
D/D |
(2,960) |
24,719 |
|
- |
|
Needham Jeffrey |
Sr. VP Commercial Business Dev |
|
2009-11-10 |
4/A |
S |
$38.93 |
$1,527,029 |
D/D |
(39,225) |
14,249 |
|
- |
|
Cohen Gary M |
Director |
|
2009-11-10 |
4 |
S |
$39.27 |
$196,388 |
D/D |
(5,000) |
15,857 |
|
- |
|
1400 Records found
|
|
Page 30 of 56 |
|
|